Vanda Pharmaceuticals (NASDAQ: VNDA) reported Q2 EPS of $0.05, $0.08 worse than the analyst estimate of $0.13. Revenue for the quarter came in at $64.4 million versus the consensus estimate of $67 million.

GUIDANCE:

Vanda Pharmaceuticals sees Q3 2022 revenue of $240-280 million, versus the consensus of $265.1 million.

For earnings history and earnings-related data on Vanda Pharmaceuticals (VNDA) click here.